(Q53198632)
English
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
scientific article published in January 2009
Statements
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany (English)
Barbara Schmalfeldt
Felix Hilpert
Jacobus Pfisterer
Andreas Du Bois
Eva-Katrin Bentz
Friedrich Kommoss
Philipp Harter
Jens Huober
Nicole Burchardi
1 January 2009
19
1
109-115
1 reference